Immuneering (NASDAQ:IMRX) CEO Buys $10,944.00 in Stock

Immuneering Corporation (NASDAQ:IMRX) CEO Benjamin Zeskind purchased 2,400 shares of the stock in a transaction on Tuesday, June 23rd. The shares were acquired at an average price of $4.56 per share, for a total transaction of $10,944.00. Following the transaction, the chief executive officer directly owned 2,315,252 shares of the company’s stock, valued at $10,557,549.12. This represents a 0.10% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Immuneering Trading Up 4.9%

Shares of IMRX opened at $4.75 on Friday. The firm has a market cap of $307.39 million, a P/E ratio of -4.06 and a beta of 0.38. Immuneering Corporation has a 12 month low of $2.90 and a 12 month high of $10.08. The stock’s 50 day moving average is $4.95 and its two-hundred day moving average is $5.24.

Immuneering (NASDAQ:IMRX) last announced its earnings results on Friday, May 15th. The company reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.30) by $0.09. Equities research analysts forecast that Immuneering Corporation will post -1.12 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the stock. Needham & Company LLC restated a “buy” rating and set a $11.00 price objective on shares of Immuneering in a research report on Monday, March 9th. Chardan Capital reissued a “buy” rating and set a $20.00 target price on shares of Immuneering in a research note on Tuesday, May 19th. Wall Street Zen downgraded shares of Immuneering from a “hold” rating to a “sell” rating in a research report on Saturday, June 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Immuneering in a research report on Wednesday. Finally, Oppenheimer reaffirmed an “outperform” rating on shares of Immuneering in a research note on Monday, June 1st. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Immuneering has a consensus rating of “Moderate Buy” and an average price target of $16.50.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in IMRX. Monashee Investment Management LLC purchased a new stake in shares of Immuneering during the third quarter worth $2,100,000. Blue Owl Capital Holdings LP purchased a new position in shares of Immuneering in the third quarter worth about $3,850,000. Hudson Bay Capital Management LP purchased a new position in shares of Immuneering in the third quarter worth about $717,000. Empery Asset Management LP purchased a new position in shares of Immuneering in the fourth quarter worth about $17,601,000. Finally, TD Asset Management Inc acquired a new position in Immuneering during the third quarter worth about $1,016,000. Hedge funds and other institutional investors own 67.65% of the company’s stock.

Immuneering Company Profile

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.